FBR Capital Maintains a 'Market Perform' on Amedisys (AMED); 1Q11 Shows There Is Still Much Work to Be Done
Tweet
Share
E-mailGet Alerts AMED Hot Sheet
Price: $100.99 --0%
Rating Summary:
6 Buy, 15 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
6 Buy, 15 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
FBR Capital maintains a 'Market Perform' on Amedisys (NASDAQ: AMED), PT $35.
FBR analyst says, "Amedisys is in the midst of adjusting from being a high-growth entity to a more efficient operator, while at the same time expanding its hospice operations and looking to grow into more areas of post-acute care. This presents a challenge for the company to simultaneously drive efficiency and broaden its addressable markets. However, we remain on the sidelines as the continued atrophy of volume and top line in the home health business has yet to experience a reversal. Management is hard at work trying to manage the operational challenges created by regulatory requirements for therapy reassessments, face-to-face interactions, and the inability to accept verbal orders. As these rules continue to evolve, we are concerned that the impact to volumes may not be as recoverable as we originally thought...We are lowering our 2011 EPS estimate by $0.28 to $3.02."
For more ratings news on Amedisys click here and for the rating history of Amedisys click here.
Shares of Amedisys closed at $35.18 yesterday.
FBR analyst says, "Amedisys is in the midst of adjusting from being a high-growth entity to a more efficient operator, while at the same time expanding its hospice operations and looking to grow into more areas of post-acute care. This presents a challenge for the company to simultaneously drive efficiency and broaden its addressable markets. However, we remain on the sidelines as the continued atrophy of volume and top line in the home health business has yet to experience a reversal. Management is hard at work trying to manage the operational challenges created by regulatory requirements for therapy reassessments, face-to-face interactions, and the inability to accept verbal orders. As these rules continue to evolve, we are concerned that the impact to volumes may not be as recoverable as we originally thought...We are lowering our 2011 EPS estimate by $0.28 to $3.02."
For more ratings news on Amedisys click here and for the rating history of Amedisys click here.
Shares of Amedisys closed at $35.18 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)
- Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
